Skip to main
  1. Stocks
  2. BridgeBio Oncology Therapeutics Inc
  3. Forecast
BBOT

BBOT Stock Forecast & Price Target

BBOT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 70%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Oncology is supported by a differentiated RAS-focused pipeline with BBO-8520, BBO-10203, and BBO-11818 aimed at high-need cancers, and the company’s strategy of combining ON/OFF inhibition with pembrolizumab or PI3Kα pathway blockade could create meaningful clinical differentiation. Recent data are encouraging, including BBO-8520 showing a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRAS G12C inhibitor-experienced NSCLC, alongside favorable liver safety, while BBO-10203 has shown a strong safety profile that may support combination development. With $315.3 million in cash and investments at 3Q26, runway into 2029, and upcoming 4Q26 and mid-2027 readouts, the company has both financial flexibility and multiple catalysts to further de-risk its portfolio.

Bears say

BridgeBio Oncology is exposed to substantial fundamental risk because all three lead programs—BBO-8520, BBO-10203, and BBO-11818—remain in Ph1 clinical trials, so any weaker-than-expected efficacy, safety, or therapeutic window data could materially undermine future approval prospects and valuation. Although BBO-8520 has shown promising KRAS G12C activity, the move into the 2L+ setting narrows the commercial opportunity versus the more attractive 1L market, while the broader KRASm space is crowded with first-generation and late-stage competitors that could limit market share. Regulatory delay risk and the need to secure favorable reimbursement further pressure the outlook, especially given that the company has no approved products and therefore limited operating leverage or commercial diversification.

BBOT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 70% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

BBOT Analyst Forecast & Price Prediction

Get the latest BBOT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BBOT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Oncology Therapeutics Inc (BBOT) Forecast

Analysts have given BBOT a Buy based on their latest research and market trends.

According to 10 analysts, BBOT has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Oncology Therapeutics Inc (BBOT)


BBOT Analyst Forecast & Price Prediction

Get the latest BBOT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BBOT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BBOT stock data and trends